DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/wg56vz/scleroderma) has announced the addition of the "Scleroderma Pipeline Highlights - 2015" report to their offering.
The latest report Scleroderma Pipeline Highlights - 2015, provides most up-to-date information on key pipeline molecules in the global Scleroderma market. It covers emerging therapies for Scleroderma in active clinical development stages including early and late stage clinical trials. The pipeline data presented in this report helps executives for tracking competition, identifying partners, evaluating opportunities, formulating business development strategies, and executing in-licensing and out-licensing deals.
Clinical Trial Stages:
The report provides Scleroderma pipeline molecules by clinical trial stages including both early and late stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.
Drug Mechanism Classes:
The report provides Scleroderma pipeline molecules by their dominant mechanism of action. This helps executives categorize molecules based on their drug class and also assess the strengths and weaknesses of compounds.
The report provides Scleroderma pipeline molecules by the Originator Company.
Short-term Launch Highlights:
Find out which Scleroderma pipeline products will be launched in the US and Ex-US till 2017.
Key Topics Covered:
1. Scleroderma Pipeline by Stages
2. Scleroderma Pipeline by Drug Class
3. Scleroderma Pipeline by Company
4. Scleroderma Phase 3 Clinical Trial Insights
5. Scleroderma Phase 2 Clinical Trial Insights
6. Scleroderma Phase 1 Clinical Trial Insights
7. Scleroderma Preclinical Research Insights
8. Scleroderma Discovery Stage Insights
10. Research Methodology
For more information visit http://www.researchandmarkets.com/research/wg56vz/scleroderma